Connect Biopharma Completes Phase 2 Enrollment for Asthma and COPD Trials
Event summary
- Completed enrollment in Phase 2 Seabreeze STAT studies for asthma and COPD, with topline results expected in September 2026.
- Cash runway extends at least one year from August 12, 2026, with $31.5 million in cash and short-term investments as of June 30, 2026.
- Phase 2 Seabreeze STAT IV study initiated in August 2026 to evaluate intravenous rademikibart for acute exacerbations.
- Net loss for Q2 2026 was $17.3 million, compared to $12.9 million in Q2 2025.
The big picture
Connect Biopharma is advancing rademikibart, a monoclonal antibody targeting IL-4Rα, for acute exacerbations in asthma and COPD. The completion of Phase 2 enrollment marks a critical inflection point as the company prepares for potential Phase 3 trials. With a focus on addressing significant unmet needs in inflammatory diseases, Connect Biopharma's strategic positioning hinges on successful clinical outcomes and regulatory alignment.
What we're watching
- Regulatory Alignment
- Whether the FDA meeting post-topline results will align on a Phase 3 program for rademikibart.
- Clinical Efficacy
- The pace at which topline data from Seabreeze STAT studies could demonstrate treatment failure reduction and lung function improvement.
- Financial Sustainability
- How Connect Biopharma will manage its cash runway beyond the current one-year projection, given increased R&D expenses.
Related topics